MSD Animal Health has announced the launch of Cepralock, a new teat sealant to complement its dry cow intramammary product Cepravin Dry Cow and wider Dairy Herd Health portfolio.  

The company says the new product is designed for use at drying off, with or without a dry cow intramammary antibiotic, and provides an important inert barrier in the teat canal to reduce significantly the risk of bacterial infection of the udder during the dry period.

Cepralock is supplied in tubes with the option of short nozzles that are designed to help avoid the risk of teat damage and incorrect administration beyond the teat canal.

The launch is also being accompanied by dry cow therapy training and a support programme for veterinary practitioners and their dairy farmer clients. This will include diagnostics and data analytics, and training will have a significant focus on correct administration and removal of teat sealant after calving, allowing vets to provide adequate reassurances to their clients around product use.

MSD Animal Health technical adviser Martin Behr said: "The dry period is a critical time for vets as they seek to help their clients in the battle to combat mastitis, which remains a significant drain on dairy herd profitability. It provides an ideal opportunity to clear up existing bacterial infections in the udder with the use of intramammary antibiotics, but it is also vital to prevent new infections over the period.

"Cows do have their own natural physical defence against infection in the form of the keratin plug that forms in the teat canal after drying off, but this is not always sufficiently effective. In a recent study it was shown that only 50% of 500 examined quarters had a fully developed keratin plug within 10 days of drying off, whilst 20% of teats remained open into the second half of the dry period. This is significant because the majority of clinical cases of mastitis that occur during the dry period do so within the first three weeks.

"Correct use of a teat sealant at drying off, immediately after the administration of the dry cow intramammary if used, will provide an effective physical barrier for the duration of the dry period, significantly reducing the chances of new infections of the udder."

According to MSD, it is estimated that less than half of dairy cows are currently given a teat sealant at drying off, despite the concept being established for a number of years and numerous farm studies providing strong evidence of their efficacy. 

Martin added: "The potential return on investment for dairy farmers of correctly applied teat sealants is clear. A single case of mastitis is estimated to cost between £70 and £250 and the average UK dairy herd suffers somewhere in the region of 50 to 60 cases per 100 cows per lactation. A correctly applied dry cow therapy programme, including the use of teat sealants, will significantly reduce the incidence of clinical mastitis, thereby providing a demonstrable return on investment.

"At MSD Animal Health we are keen to help veterinary practitioners promote best practice in dry cow therapy, including the adoption of the correct protocols and application procedures. Therefore we are supporting the launch of Cepralock with the offer of Continuous Professional Development for veterinary practitioners on all aspects of dry cow therapy, including correct use of teat sealant and its removal after calving."

Cepralock teat sealant is available to veterinary practices in packs of 24 tubes and 120 tubes.

For more information about Cepralock or MSD's Dry Cow Management Support package for vets and farmers, contact your Account Manager.

Eurovet Animal Health has announced that it is bringing a veterinary licensed vitamin K1 (phytomenadione) injectable preparation to the UK.

Eurovet says the new preparation, available from the wholesalers by Monday at the latest, will ensure that the previous supply problems of vitamin K1, will be overcome.

According to the company, the intravenous route is the only route to ensure a 100% bioavailability of vitamin K1 almost immediately and in a crisis situation is the best route of treatment. During anticoagulant poisoning, the coagulation factors are present in the body but are not functional. The faster vitamin K1 enters the blood flow, the quicker the coagulation function is restored.

Ruth Vernon, Technical Services Manager for Eurovet said: "We also plan to bring veterinary licenced vitamin K1 tablets to the UK market later in the year, allowing them to be ordered direct from veterinary wholesalers. The future continuity of supply represents a significant improvement on the current situation."

Anticoagulant rodenticide poisoning is the second most common query received by the VPIS. Alexander Campbell, Head of Service at VPIS, said: "The Veterinary Poisons Information Service receives well over 1000 telephone enquiries per annum from UK veterinary professionals seeking advice on how to manage potential and accidental exposures to anticoagulant rodenticides in a variety of animals - mainly pet dogs. Whilst most cases require basic assessment, first-aid and precautionary laboratory tests, an inevitable few develop serious intoxication and need long-term treatment. Vitamin K1 is a mainstay of therapy in these instances, and the availability of licensed veterinary-specific products in the UK is a major advance. Previously, preparations licensed for human use were often the only option when these could be sourced. Anything that ensures ready supply and facilitates speed of therapy for severe cases has to be welcomed."

There are over 500 anticoagulant rodent killing preparations available across Europe. They are available ready to use, as coated cereals, bait blocks, tracking powders, semolina formats or concentrates (which are reserved for professional use). Following cut backs in local council spending on pest control, the National Pest Technicians Association identified in a recent survey* that there is a 'worrying increase in poorly-managed DIY rodent control'.

*The NPTA National Rodent Survey 2009/2010

BEVA has announced the launch of CPD courses designed to help equine and mixed vets get back into equine practice after a break from clinical work.

Sarah Gasper, BEVA’S Learning Manager said: "Many of us on the BEVA education team understand exactly what it’s like to return to practice whether after a career break, paternity/maternity or sickness leave. We also understand the specific challenges of moving from mixed into equine practice. 

"We have created these courses to help make the transition back to work as smooth as possible. We’ve tried to incorporate everything we wish we had had access to when we returned to practice!"

Reinvigorate your approach to equine practice will be held on 12th March 2019 at Lythe Hill Hotel, Haslemere. The lecture and forum based course will explore the latest advances in internal medicine, orthopaedics, and sports medicine, and how to apply them to develop evidence-based clinical approaches to common and emergency scenarios in practice. 

Getting (back) into equine practice will be held on 13th March 2019 at Liphook Equine Hospital, Hampshire. This entirely practical day of CPD will all be about improving the confidence of established equine vets and for vets returning to work following a career break. The course will focus on the practical procedures that an established equine ambulatory vet might be expected to perform on a regular basis. In a new approach to CPD we are trialling a system where delegates can shape part of this unique CPD day for themselves, with an online poll pre-course to select from a choice of practicals. 

Both courses will have childcare facilities to help support parents wishing to attend CPD.

BEVA will also be running a course on the fundamentals of sedation, field anaesthesia and castration on 27th and 28th March 2019 at World Horse Welfare, Snetterton, Norfolk. This 'hands-on' course is designed for new or recent graduates or those in mixed practice with varied levels of equine work. It comprises evening lectures on the first day to free up more time for hands-on training on day two. It will cover sedation and field anaesthesia required for common field surgery such as castration, both in theory and in a practical session, with the equine welfare charity venue able to provide a high number of colts for castration work. Nerve blocks and regional anaesthesia for other common procedures will also be covered on cadavers. 

For further information on BEVA’s new CPD courses visit www.beva.org.uk/cpd

Research published in the Journal of Small Animal Practice (JSAP) has revealed that UK dogs eating raw meat diets have a higher risk of Salmonella and antimicrobial-resistant Escherichia coli being found in their faeces than dogs fed cooked food. 

For the research¹, 190 faecal samples were collected from dogs in 140 households (114 samples from raw fed dogs and 76 from non-raw fed dogs).

Salmonella species was detected in 4% of the samples (all raw fed) and antimicrobial-resistant E. coli was detected in 40% of all dogs, but in 62% of raw fed dogs.

The authors say that statistical analysis confirmed that this represented a significantly higher prevalence of AMR E. coli, including multidrug resistance and third generation cephalosporin resistance, and Salmonella species in dogs fed raw compared to non-raw meat diets.

The authors concluded that strategies should be implemented to increase the awareness of the risks of feeding raw meat diets to dogs, to reduce any potential risk to owners, their families, and their pets.

Nicola Di Girolamo, Editor of JSAP says: “In this study, an association between raw meat diets in dogs and faecal carriage of potentially dangerous enteric bacteria has been observed.

"Readers should keep in mind that cross-sectional studies such as this one lay the basis for additional research more suited to prove causality.”

Reference

1. Groat, E.F., Williams, N.J., Pinchbeck, G., Warner, B., Simpson, A. and Schmidt, V.M. (2022), UK dogs eating raw meat diets have higher risk of Salmonella and antimicrobial-resistant Escherichia coli faecal carriage. J Small Anim Pract, 63: 435-441. https://doi.org/10.1111/jsap.13488 

Protexin has announced that preliminary data from a clinical trial supports the use of Denamarin^® to protect against lomustine (CCNU)-induced hepatotoxicity in dogs.

The study is being performed at the University of California-Davis, Veterinary Medical Teaching Hospital, and the initial results were recently presented at the American College of Veterinary Internal Medicine (ACVIM) Annual Forum. Marketed in the UK by Protexin, Denamarin is the combination of S-adenosylmethionine (SAMe) and silybin.

According to the company, most dogs treated with the chemotherapeutic agent CCNU experience liver enzyme elevation. Elevation of certain liver enzymes such as alanine transferase (ALT) is a key indicator of liver trauma; significant enzyme elevation may lead to a discontinuation, delay, or reduction in chemotherapy. The ongoing clinical trial was designed to evaluate Denamarin as a hepatoprotectant in dogs diagnosed with neoplasia that are undergoing CCNU therapy.

The trial consists of two groups of randomly assigned dogs. Dogs in Group 1 receive Denamarin beginning at the start of CCNU therapy. Group 2 dogs do not receive Denamarin unless they develop a Grade IV hepatotoxicity.

Results of a planned interim analysis completed on the first 30 dogs enrolled revealed that starting Denamarin when CCNU therapy was instituted (Group 1 dogs) appeared to provide hepatoprotection. While the mean post-therapy ALT elevation for Group 1 was 119 IU/L (p=0.1), for Group 2 dogs, the post-therapy ALT level was 815 IU/L (p=0.046). Chemotherapy was altered due to elevated liver enzymes in three Group 2 dogs but only one dog in Group 1.

Janine Barlow, Technical Manager at Protexin said: "We are extremely pleased by the initial findings of this research. The use of Denamarin with chemotherapy looks to help protect liver function allowing for successful completion of therapy and hopefully a longer, happier life for the pet. We look forward to the results of the full study."

Protexin says the SAMe and silybin in Denamarin support and maintain hepatic function by mechanisms including increasing levels of glutathione, the liver's main detoxifying agent; promoting protein synthesis; and stimulating bile flow. Denamarin is useful as part of a polymodal approach to the management of liver health.

Denamarin is available for both dogs and cats in an enteric-coated tablet.

A new veterinary practice start up which will use technology to improve both the pet owner experience and the quality of working life for its employees has raised £7M in seed capital and is set to open its first two clinics in London. 

Creature Comforts will be using the cash both to open the clinics and build a proprietary app which will give owners seamless 24/7 access to veterinary care, whilst allowing vets to work more flexibly and more often from home. 

VetSurgeon.org caught up with Russell Welsh (pictured), co-founder of the new business alongside Daniel Attia. 

Russell said: "During the pandemic, there was a recognition that employers needed to do more to attract and retain veterinary staff, and so there has been a move towards more flexible working and better employment packages.

"The problem is that we then saw a massive increase in the number of pets, and the profession is struggling to meet demand.

"On top of that, the corporatisation of the profession has meant that both staff and owners often feel less connected with each other.

"We think the answer lies in independent practices making better use of technology to reduce the workload on veterinary staff whilst creating a better, seamless, more personal experience for pet owners.

"There are of course companies offering online consultations, but they tend to be stand alone services, or belong to corporate groups. 

"What we're doing differently is developing our own system so that we don't lose control of any stage in the client journey and can make sure the quality of care, after care and service is consistently high.

"We'll also be putting together a share option scheme, so our employees will really feel a proper sense of ownership."

https://www.creaturecomforts.co.uk 

Researchers at the Royal Veterinary College report that they've made a significant breakthrough in the search for a durable treatment for Duchenne muscular dystrophy (DMD).

Working in collaboration with researchers at University of Texas, Southwestern (UTSW) Medical Center, the team has succeeded in using gene editing techniques on dogs to restore the expression of the dystrophin protein that is absent in DMD patients’ muscles to levels that could be life changing.

DMD is the most common, fatal, genetic disease that affects children. The same disorder also occurs in many dog breeds. It is caused by mutations in the gene that encodes dystrophin, a crucial protein that helps protect muscle fibres and the heart when they contract. Patients with the disease produce effectively no dystrophin protein, so their muscles and heart become damaged during contraction, leading to inability to walk, skeletal deformities, breathing problems and heart failure. Patients with DMD have a life expectancy that does not go far beyond their twenties.

Researchers say that this preliminary research, published in Science, demonstrates an approach that could lead to an effective, in principle one-time treatment for DMD for the most common genetic mutations affecting human patients. Through a single intravenous injection, researchers have been able to modify the dystrophin gene in many muscles of the body, including the heart, with the result that some muscles now had almost the normal amounts of dystrophin protein.

The team, led by Eric Olson, Ph.D., professor and chair of the Department of Molecular Biology at UTSW Medical Center and founder and chief science advisor of Exonics Therapeutics, and Richard Piercy, Ph.D., MRCVS, Professor of Comparative Neuromuscular Disease at the RVC, identified a naturally-occurring mutation in the dystrophin gene in a dog brought to the RVC’s Small Animal Referral Hospital.

Working now with relatives of this first dog, the combined group has used a technique called ‘SingleCut CRISPR gene editing’, where the researchers target a specific region of the subject’s own DNA. Harmless viruses encoding the gene-editing protein CRISPR/Cas9 were used to express the enzyme in muscle to cut the dogs’ own DNA at a precise location in the dystrophin gene through use of a molecular guide. The body’s own processes then repair the cut, which results in removing the negative effects of the existing mutation.

The researchers have demonstrated that dogs treated in this way had restored ability to produce large amounts of the dystrophin protein in their muscles and heart, and in the dog with the highest dose, cardiac muscles were found to have restored dystrophin protein to up to 92% of normal amounts after the single treatment.

The team believes this is the first time that this form of gene editing therapy has been conducted after birth in an animal larger than a rodent. With further longer-term research, efficacy and safety testing, it is hoped that this breakthrough will have human application. This treatment may be a significant step toward developing a gene editing therapy to repair genetic mutations for DMD, as well as a range of diseases caused by genetic mutations.   

Richard Piercy, Professor of Comparative Neuromuscular Disease at the RVC, said: "Researchers have been looking for an effective and durable treatment for Duchenne muscular dystrophy for many years. This SingleCut gene editing approach, pioneered by Dr. Eric Olson’s group, has the potential to be a one-time treatment that could restore dystrophin protein. It is hugely exciting that through a single intravenous injection we’ve been able successfully to modify the dogs’ own DNA so they start generating dystrophin protein again. There is more work to be done, but with this exciting breakthrough, we feel we are a significant step closer to finding an effective treatment.

"A great many genetic diseases affect humans, dogs and other species - many, like DMD - with tragic consequences and this form of gene editing treatment might well be applicable in many of them. We’re hopeful that we’re paving the way for future research into treating some of the most serious genetic conditions that affect us today."

Irish small animal practitioner Stuart Fitzgerald MVB MANZCVS has launched the MobiVet Veterinary Formulary app for Android devices.

Available for download now, the MobiVet Veterinary Formulary App is designed to make drug calculations and prescribing faster, easier and safer. It contains dose rate and interval data for over 250 drugs commonly used in small animal practice.

Searchable by drug name or trade names, with species-specific dosing information, the app calculates doses based on the patient type, weight, or body surface area as appropriate. MobiVet also provides a checklist of known relevant drug interactions for each medication, to prevent prescribing errors.

Stuart says an iOS version is in production.

To download the Android version, visit: https://play.google.com/store/apps/details?id=com.project.user.drug_formulary&hl=en

Three ex-partners of the Willows Veterinary Group have launched North Star Vets, a new veterinary group which will give vets an opportunity to own a stake in their practice without any capital investment. 

MsRCVS Sean Cleary and Richard Thomas, and accountant Jane Platt have opened their first practice, Burford Lane Vets in Cheshire, and now plan to open 10 more practices over the next five years, two in Spring 2022

Burford Lane Vets is headed up by Pieter De Villiers MRCVS, who has become an equity owner, supported by a team of nine vets, nurses and receptionists.

Sean said: “Our vets benefit from our many years of clinical, financial, human resources and procurement experience and have the opportunity to add the finishing touches to a state-of-the-art practice, where no expense has been spared on the fit out and equipment.

"Everything from finding a property, negotiating the lease, fitting out the practice and health and safety is taken care of.

"It means our equity partners can enjoy being fantastic vets and reap the financial rewards that brings, and we are here to support the practice and take care of all the administration, procurement, marketing and everything else that goes into running a successful business."

Sean added: “We have benefited from the shift in the industry that saw veterinary groups acquired by large corporate businesses.

"However, this has inadvertently made it difficult for the next generation of vets to follow the traditional route of buying into a practice as they progress from a junior role to partner, as corporate interest has pushed the values of practices to unaffordable levels for most vets.

"We want to bridge that gap and give a leg up to vets who want to be masters of their own destinies, without the difficulty of starting from scratch or having to find a huge initial investment.”  

Sean says he thinks there are a great many vets who would like to launch their own practice.

However, starting from scratch is fraught with risk, expense, and complexity.

Sean added: “Our innovative model helps great vets set up in business as leaders of their own practice and our unique offering is already attracting interest from high-calibre individuals.

"We would encourage any colleagues out there who feel they would like to join us in our new venture to get in touch via our website.” 

Sean concluded: “The business acumen we have built up over our many years of working in the industry enables us to provide practical support, mentorship and guidance for vets through every step of the process, and that’s something we’re passionate about.

"The directors will be working across all practices to provide support whenever it’s needed. We are in it for the long haul, not just the initial set up stage, and we will become a part of every practice that opens.

“We take a real pride in being the solution to fix the broken practice ownership model and North Star Vets will empower ambitious vets to enjoy a better and more successful future, which in turn will translate into the standard of care our clients enjoy.”  

The RCVS Disciplinary Committee has removed a veterinary surgeon formerly working in Lincolnshire from the Register, after finding him guilty of serious professional misconduct for drink-driving related convictions, failing to inform his employer of these convictions, and driving whilst disqualified.

Jaroslaw Slominski, a former employer of Grants Veterinary Services plc, chose not to attend the three-day hearing. The Committee considered whether to proceed with the case, using criteria identified by the Court of Appeal in R v Jones (Anthony) in 2002 and confirmed by the House of Lords. It concluded it was in the interests of justice that the hearing should go ahead.

The charges related to two convictions Mr Slominski received on 17 March 2010 at Lincoln Magistrates Court: failure to provide a specimen of breath for analysis and driving without due care and attention (after his vehicle collided head-on with another car). Mr Slominski failed to inform his employers of these convictions, as he was contractually obliged to do, and that he was now disqualified from driving.

Having heard evidence from Mr Slominski's line manager, the Committee also found that he had driven his employer's vehicle whilst disqualified, although it could not be sure that he had done so on all the occasions alleged. Therefore, the Committee did not go on to consider an alternative part of the charge - that Mr Slominski had dishonestly claimed money from his employer by falsely submitting expenses claims.

Disciplinary Committee Chairman Prof Peter Lees said: "The combination of factors in this case, namely, the serious nature of his conviction in failing to provide a specimen of breath, his subsequent premeditated conduct in not informing his employers and driving whilst disqualified should be treated by the profession very seriously. The Committee has concluded that the combination of the conviction and the conduct is incompatible with Mr Slominski practising as a veterinary surgeon."

The Committee directed that Mr Slominski's name be removed from the Register.

TheraVet S.A., a Belgian company which specialises in the management of osteoarticular diseases in pets, has announced the launch of Biocera-Vet, an injectable bone substitute for use in orthopaedic surgery. 

The company says that despite the development of alternatives to natural bone grafting, such as allografts and synthetic products, autologous bone graft is still considered the standard. However, it has a number of disadvantages, such as donor site morbidities and lameness, limited availability of graft volume (particularly in small size pets) and additional surgical time.

Biocera-Vet is a new bone substitute indicated in surgical procedures where bone grafting is necessary, such as arthrodesis, complex fractures, corrective osteotomy used in correction of limb deformities or as add-on to Tibial Tuberosity Advancement (TTA).

Biocera-Vet is an injectable synthetic self-hardening calcium-phosphate cement combining osteo-inductive, osteo-conductive and osteo-integrative properties designed to support a fast and strong consolidation.

TheraVet says Biocera-Vet also presents an excellent safety profile thanks to its biocompatibility, reduced comorbidities and superior ergonomics which save a significant amount of surgical time.

Dr Olivier Stiévenart, an orthopaedic veterinary surgeon at Surgivet in Belgium said: "Using Biocera-Vet has enabled us to optimise our patient care considerably, by reducing the operating time by at least 30 minutes. The use of an efficient and rapid bone substitute represents a real progress in terms of both operations and the animal’s quality of life".

Julie Schurgers, Chief Commercial Officer of TheraVet, said: "Biocera-Vet is a unique product on the veterinary bone substitute market, combining outstanding bone consolidation properties with an excellent safety profile and superior ergonomics. We are very excited today to announce its commercialisation on the market and are convinced that this innovative product will significantly improve the daily practices of veterinarians, for the well-being of patients and their owners."

The product is now available in Belgium, and will be rolled out in France and the Netherlands shortly, with the rest of Europe following later in 2021 / 2022.

For more information, visit: https://www.thera.vet/en/biocera-vet

Ceva Animal Health has launched Hepatosyl Plus, a development of the liver support supplement for cats and dogs.

Hepatosyl Plus contains the same ingredients as the original product but now also includes Silybin. According to the company, Silybin is the most active isomer of Silybum marianum (milk thistle) which acts as an antioxidant by increasing cellular superoxide dismutase. It joins S-adenosylmethionine (SAMe) and Vitamin E to create a triple antioxidant approach to liver support, helping to neutralise free radicals within the liver. Ceva also says Hepatosyl Plus is the only liver supplement to contain Vitamin K, which is needed by the liver for the production of clotting factors II, VII, IX and X, making it ideally suited for pre- and post-anaesthetic liver support.

Hepatosyl Plus is available in 50mg, 100mg and 200mg sprinkle capsules.  For anaesthetic support, Hepatosyl Plus should be administered for one week prior to and following anaesthesia.  For long-term use, the capsules should be given once daily for 2-3 months and then reduced to every other day for ongoing maintenance.

For further information, please contact your local CEVA Animal Health territory manager or call 01494 781510.

A new study by researchers at Nottingham Trent University suggests that the number of brachycephalic dogs being taken in by UK rescue and rehoming centres has doubled over three years.

For the study, the researchers analysed rehoming adverts placed on the websites of 16 Dogs Trust and RSPCA centres in 2015 and 2018. Data was collected on 1793 dogs across the 16 centres.

The percentage of dogs classified as 'extreme brachycephalic' using the Kennel Club definition increased from 2.76% (n=24) in 2015 to 5.19% (n=48) in 2018.

The researchers speculate that owners may be passing on the financial burden of caring for and treating chronic health issues in brachycephalic dogs to the rehoming charities.

Dr Anne Carter, Senior Lecturer in Animal Science at Nottingham Trent University said: "The increasing numbers and rising popularity of brachycephalic breeds is already influencing the demographic spread in rescue centres. This pattern that is likely to continue, particularly as these dogs reach 3–4 years old, which we have found is the most common age for dogs being relinquished.

"Differing breeds require highly contrasting intensities of care, housing, and particularly veterinary care. Owners may often choose brachycephalic dogs with limited consideration for their potential health conditions. These dogs then enter rescue centres, placing additional strain on resources due to cost of treatment and additional length of stay for recovery.”

Reference

1. Anne J. Carter & Jaime H. Martin (2020) Demographic Changes in UK Rescue Centre Dog Population between 2014 and 2018, Journal of Applied Animal Welfare Science, DOI: 10.1080/10888705.2020.1839755